Clinical efforts are ongoing to produce more specific BIRC5 inhibitors, and our results indicate that patients with DNMT3A-mutant T-ALL would be an ideal patient population to trial such agents. The gene discussed is DNMT3A; the disease is acute lymphoblastic leukemia.